Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 C383R FGFR2 N550D |
Therapy | Lirafugratinib |
Indication/Tumor Type | intrahepatic cholangiocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 C383R FGFR2 N550D | intrahepatic cholangiocarcinoma | sensitive | Lirafugratinib | Preclinical - Pdx | Actionable | In a preclinical study, Lirafugratinib inhibited tumor growth in a patient-derived xenograft (PDX) model of intrahepatic cholangiocarcinoma harboring FGFR2 C383R and FGFR2 N550D (PMID: 39226398). | 39226398 |
PubMed Id | Reference Title | Details |
---|---|---|
(39226398) | Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies. | Full reference... |